Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share

3 Months Ended

Mar. 31, 2019

Loss per share

Loss per share

Note 5 — Loss per share

The numerator for the basic and diluted income (loss) per share is as follows (in thousands):


	Three months ended
	March 31,
	2019		2018
Net income (loss) attributable to ordinary shareholders	$	(27,412)	$	(21,078)
Numerator for basic income (loss) per share		(27,412)		(21,078)
Numerator for diluted income (loss) per share		(27,412)		(21,078)

The denominator for the basic and diluted income (loss) per share is as follows:


	Three months ended
	March 31,
	2019	2018
Denominator for basic income (loss) per share - Weighted average shares outstanding	627,945,243	562,381,995
Effect of dilutive securities:
Employee stock options	103,848,778	89,203,915
Denominator for diluted income (loss) per share	731,794,021	651,585,910

The dilutive effect of 103,848,778 and 89,203,915 stock options have been excluded from the diluted loss per share calculation for the three months ended March 31, 2019 and 2018, respectively, because they would have an antidilutive effect on the loss per share for the period.